BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, February 5, 2026
Home
»
Authors
» Cormac Sheridan
Cormac Sheridan
Articles
ARTICLES
Arpida, Combio Collaborate For Antibiotics Discovery
Oct. 16, 2002
By
Cormac Sheridan
Cytos Going Public By Way Of Merger With Swiss Company
Oct. 2, 2002
By
Cormac Sheridan
Investors Hammer Genmab Stock Following Failure Of Lead Drug
Oct. 2, 2002
By
Cormac Sheridan
Pharming Raises EUR8.2M In Equity, Debt, Prepares To Exit Moratorium
Oct. 2, 2002
By
Cormac Sheridan
Investors Hammer Genmab Stock Following Failure Of Lead Drug
Oct. 2, 2002
By
Cormac Sheridan
Cytos Going Public By Way Of Merger With Swiss Company
Oct. 2, 2002
By
Cormac Sheridan
Pharming Raises EUR8.2M In Equity, Debt, Prepares To Exit Moratorium
Oct. 2, 2002
By
Cormac Sheridan
Eirx Pharma Formed Through Three-Way Anglo-Irish Merger
Sep. 25, 2002
By
Cormac Sheridan
Modex, IsoTis Plan To Merge Programs In Orthopedics, Skin
Sep. 25, 2002
By
Cormac Sheridan
Eirx Pharma Formed Through Three-Way Anglo-Irish Merger
Sep. 25, 2002
By
Cormac Sheridan
View All Articles by Cormac Sheridan
